The patients will be relapsers but not necessarily cirrhotic. I...

The patients will be relapsers but not necessarily cirrhotic. I would think they would have relapsed from the Int/rib regime. Just a guess of course.

No doubt they (the first two non therapeutic cohorts) will be given the opportunity to get the best available treatment sometime after their final tests. That would be the Sovaldi/Ledipasvir regime or perhaps even the new AbbVie regime. I would guess that Duke may have access to these prior to general approval??

Wouldn't it be fantastic if the sub dose actually worked?

I admire anyone who is willing to undergo the first and second sub doses. They are true champions.